Company to provide overview of lead investigational asset, BRIMOCHOL™, for the treatment of presbyopia
Will introduce expanded portfolio of new drug candidates and an improved ophthalmic drug delivery platform targeting an array of ophthalmic conditions
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10:00 a.m. to 2:00 p.m. ET at Convene, 530 Fifth Avenue at 45th Street in New York City.
During the Capital Markets Day, Ben Bergo, co-founder and chief executive officer, Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of research and development, and Carey Powers, vice president of marketing, and leading eye care experts will discuss the company’s lead candidate, BRIMOCHOL™, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. Presenters will share new data including market sizing and market research insights from consumers and health care providers. Leading experts in ophthalmology and optometry will discuss unmet needs and emerging advances in the treatment of presbyopia and other ophthalmic conditions. Additionally, management will present Visus’ new generation of drug candidates for glaucoma and age-related macular degeneration, and an improved ophthalmic drug delivery platform that can help optimize patient outcomes for hard-to-treat eye diseases.
A live webcast of the presentation and question and answer sessions can be accessed on Visus Therapeutics’ website under “Livestreaming Event” in the News page at www.visustx.com, or directly at the Capital Markets Day registration site. Please access the Company’s website at least 15 minutes ahead of the event to register and install any necessary audio software. The conference call will also be available for replay for one month on the Company’s website.
To participate in the Visus 2021 Capital Markets Day via phone, please dial the following numbers prior to the start of the conference at: 877-405-1239 or 201-389-0851
Presenters and panelists include:
- Ben Bergo: Co-founder & CEO, Visus Therapeutics
- Rhett Schiffman, MD,MS, MHSA: Co-founder, Chief Medical Officer and Head of Research & Development, Visus Therapeutics
- Carey Powers: Vice President of Marketing, Visus Therapeutics
- Eric D. Donnenfeld, MD: Founding Partner, Ophthalmic Consultants of New York and Ophthalmic Consultants of Connecticut, Clinical Professor of Ophthalmology, New York University Medical Center
- Ike Ahmed, MD, FRCSC: Prism Eye Institute / Assistant Professor, Fellowship Director Kensington Eye Institute, University of Toronto
- Zaina Al-Mohtaseb, MD: Associate Professor, Ophthalmology Department, Baylor College of Medicine
- April Jasper, OD, FAAO: Owner, Advanced Eyecare Specialists / Chief Editor of Optometric Management
- Haejin Shin: Principal, IQVIA Strategic Advisory Services
About Visus Therapeutics
Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter (@VisusTx) and Instagram.
Contacts
Business & Biotech Press:
Doug Hochstedler
Doug.Hochstedler@PorterNovelli.com
(317) 645-8665
Eye Care Trade Press:
Michele Gray
michele@mgraycommunications.com
(917) 449-9250
Investor Relations:
Paul Sagan
psagan@lavoiehealthscience.com
(617) 865-0041